Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Oct 2, 2023

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

Sep 18, 2023

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Sep 11, 2023

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Sep 5, 2023

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Aug 14, 2023

Cellectar Provides a Research and Development Program Summary

Jun 12, 2023

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

Mar 9, 2023

Cellectar to Participate at Upcoming Banking Conferences

Mar 8, 2023